SLS Corp Cytrx sells $1.3M worth of shares
Jan 08, 2026, 5:36 PM
0.00%
What does SLS do
SELLAS Life Sciences Group, a clinical stage biopharmaceutical company based in New York, develops immunotherapeutics for cancer, including galinpepimut-S and SLS009. The company went public in 2008 and employs 16 staff.
Corp Cytrx sold 500,000 shares of SLS on 22 December at $2.65 per share, worth a total of $1.3M. They now own 2,593,881 SLS shares, or a 16% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.